ENDPOINTS

Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts

Plus, news about Repare Therapeutics, DCx Biotherapeutics, Bloomsbury Genetic Therapies and Zucara Therapeutics: Arvinas drops planned late-stage trials: The protein degrader specialist, along with its partner Pfizer, canceled plans for a ...

May 1, 2025 - 15:46
 0
Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts
Plus, news about Repare Therapeutics, DCx Biotherapeutics, Bloomsbury Genetic Therapies and Zucara Therapeutics: Arvinas drops planned late-stage trials: The protein degrader specialist, along with its partner Pfizer, canceled plans for a ...
Read More

Tags:

Previous Article

Does science have a future in the US?

Next Article

Teladoc acquires UpLift for $30M, releases first quarter results

Related Posts

FDA approves Johnson & Johnson's rare disease drug that's expected to compete with argenx and UCB

FDA approves Johnson & Johnson's rare disease drug that...

Apr 30, 2025  0

Updated: Novartis to buy Regulus Therapeutics for up to $1.7B

Updated: Novartis to buy Regulus Therapeutics for up to...

Apr 30, 2025  0

Summit, Akeso report another Phase 3 win for PD-1xVEGF approach in lung cancer

Summit, Akeso report another Phase 3 win for PD-1xVEGF ...

Apr 23, 2025  0